Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80,702,987
-
Total 13F shares
-
19,234,412
-
Share change
-
-1,434,639
-
Total reported value
-
$216,961,860
-
Put/Call ratio
-
150%
-
Price per share
-
$11.28
-
Number of holders
-
82
-
Value change
-
-$28,739,223
-
Number of buys
-
58
-
Number of sells
-
32
Institutional Holders of Altimmune, Inc. - Common Stock (ALT) as of Q4 2020
As of 31 Dec 2020,
Altimmune, Inc. - Common Stock (ALT) was held by
82 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,234,412 shares.
The largest 10 holders included
VR Adviser, LLC, BAKER BROS. ADVISORS LP, Capital World Investors, UBS Group AG, CREDIT SUISSE AG/, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, BlackRock Inc., Invesco Ltd., and Acuta Capital Partners, LLC.
This page lists
82
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.